Meridian Bioscience — Q1 FY2022 Earnings Presentation
15 slides from Meridian Bioscience's earnings presentation, Feb 4, 2022
Slide 1: FY2022 Q1 Results
FY2022 Q1 Results February 4, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A
Slide 3: Non-GAAP Financial Measures
Certain financial measures presented in this presentation, such as operating expenses, operating income, operating margin, net earnings and net earnings per diluted share, each on an adjusted basis, excluding as applicable the effects of changes in fair value of acquisition consideration and selecte
Slide 4: Q1 FY2022 Business Highlights
Launched Lyo-Ready™ sample specific master mixes for saliva Received FDA EUA for Revogene® SARS-CoV-2 assay Received FDA 510(k) clearance for Curian® Campy Q1 FY2022 Business Highlights Diagnostics Life Science
Slide 5: FY2022 First Quarter Earnings Summary
FY2022 First Quarter Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2022 FY2021 Change Net revenues $88,341 $92,917 -5% Gross margin % 56% 66% -10 pts Operating expenses(1) Ratio $28,595 32% $24,610 26% +16% +6 pts Operating income Margin % $20,564 23% $36,938 40% -44% -17
Slide 6: FY2022 First Quarter Operating Segment Highlights
FY2022 First Quarter Operating Segment Highlights ($000’s) Diagnostics segment (Adjusted Non-GAAP) FY2022 FY2021 Change Net revenues $33,204 $30,321 +10% Operating income / (loss) Margin % ($2,612) NMF ($135) NMF NMF NMF Diagnostics segment net revenues by: Technology: Molecular assays $4,752 $4,590
Slide 7: FY2022 Fiscal Year Guidance
FY2022 Fiscal Year Guidance Meridian Bioscience Diagnostics Life Science Prior Guidance (11/12/2021) Updated FY2022 Guidance Meridian Bioscience Consolidated net revenues: $315 to $330 Million Adjusted operating margin: 21% to 23% Adjusted net earnings per share*: $1.10 to $1.30 Diagnostics Net reve
Slide 8: Diagnostics R&D Pipeline
Diagnostics R&D Pipeline (as of 12/31/2021) Breath Immunoassay Molecular Blood Chemistry Feasibility Development Clinicals FDA Liver MBT PMA C. difficile Shiga Toxin Streptococcus pneumoniae / Legionella RI Panel GI Panel COVID-19 EUA(2) PediaStat Analyzer Lead Expected FY22 FDA Submissions Shiga To
Slide 9: H. pylori Opportunity
H. pylori Opportunity ~~
Slide 10: H. pylori Opportunity: Testing Gap
H. pylori infection Lifelong infection unless treated Causes >90% duodenal ulcers Causes >85% gastric ulcers Infected persons have 2- to 6-fold increase risk for gastric cancers and/or mucosal-associated lymphoid type lymphoma (MALT) Classified as a carcinogen by WHO H. pylori Infection Prevalence 2
Slide 11: Diagnostic Test Comparison
Features Endoscopy + RUT/Histology/ Culture Serology Urea Breath (UBT) Stool Antigen (HpSA) Relative invasiveness Severe Low Non Non Technical skill level Physician and Pathologist/Lab personnel Lab personnel Nurse or Lab personnel Lab personnel Rapid/Ease of use ü ü ü Detect active infection ü ü ü
Slide 12: Accuracy of H. pylori Detection Methods
Accuracy of H. pylori Detection Methods Test Method Sensitivity Specificity Endoscopy – Culture 77-95% 95-100% Endoscopy – CLO/Rapid Urease Test 89-95% 90-98% Endoscopy – Staining 80-95% 98-100% Serology 80-95% 79-90% Urea Breath Test 95-100% 90-99% Stool Antigen 91-100% 92-98%
Slide 13: H. pylori Diagnostics: Serology Antibody Testing
H. pylori Diagnostics: Serology Antibody Testing Serology is NOT clinically recommended by any guidelines; cannot detect active infection. Serology testing is often NOT reimbursed. Serology users tend to “inappropriately” use serology to rule out H. pylori first and then reflex positive serology tes
Slide 14: SS irenemcne
SS irenemcne
Slide 15: Contact
Contact: [email protected]
Meridian Bioscience — Q1 FY2022 Earnings Presentation on 6ix